Pre-market Hot Trades in US Stocks
Credo Tech is up 3.26% in pre-market trading. Based on recent important news:
<ol>
<li>
On September 17, Lip Bu Tan, a director of Credo Technology Group, sold shares of the company's common stock, leading to increased market attention on the company's internal movements. This move may raise investor concerns about the company's future development, affecting stock price volatility. Data source: EDGAR system.
</li>
<li>
On September 16, William Joseph Brennan, the president and CEO of Credo Technology Group, also sold common stock, further intensifying market scrutiny of the company's internal transactions. Data source: EDGAR system.
</li>
<li>
On September 18, investors with ample funds in the market took a noticeably bullish stance on Credo Technology Group, with active options trading indicating confidence in the company's future growth potential. Data source: Market Watch. The growth potential of AI infrastructure is significant.
</li>
</ol>
Top Gainers in Pre-market US Stocks
Aptevo Therapeutics is up 89.36% in pre-market trading. Based on recent key news:
<ol>
<li>
On September 16, Aptevo Therapeutics announced that the third cohort of its Phase 1b/2 RAINIER trial for acute myeloid leukemia (AML) achieved a 100% remission rate, causing the stock price to rise by 57%. The study tested Aptevo's CD123 x CD3 bispecific antibody in combination with venetoclax and azacitidine for newly diagnosed AML patients.
</li>
<li>
On September 16, Aptevo's trading volume surged, with approximately 34 million shares changing hands, compared to an average of about 165,000 shares over the past three months, indicating a strong market reaction to the news.
</li>
<li>
On September 17, despite facing financial challenges, including declining revenue and high leverage, Aptevo's positive progress in its oncology pipeline provides potential upside for the future. The biotechnology industry is highly volatile and requires caution.
</li>
</ol>
89bio is up 82.80% in pre-market trading. Based on recent important news:
<ol>
<li>
On September 18, Roche announced it would acquire 89bio for $14.50 per share in cash, with a total transaction value of up to $3.5 billion. This news significantly boosted 89bio's stock price. Data source: Zhitong Finance.
</li>
<li>
On September 18, 89bio's key drug pegozafermin is in late-stage development and is expected to become the best treatment for metabolic dysfunction-associated fatty liver disease. The potential of this drug has attracted market attention. Data source: Zhitong Finance.
</li>
<li>
On September 18, Wall Street rated 89bio stock as a strong buy, with a target price of $27, indicating an upside potential of 234.16%
This rating further enhances investor confidence. Data source: TipRanks. The biopharmaceutical industry is active in mergers and acquisitions, with increased market volatility.
</li>
</ol>
AquaBounty Technologies rose 54.39% in pre-market trading. According to recent key news:
<ol>
<li>
On September 18, technical analysis of AquaBounty Technologies showed a neutral outlook, with mixed momentum indicator signals. The negative price-to-earnings ratio and lack of dividends further affect the stock's attractiveness. Improvements in operational efficiency and cash flow management are crucial for enhancing its financial health.
</li>
<li>
AquaBounty Technologies focuses on the development and commercialization of genetically modified fish to improve aquaculture productivity.
</li>
<li>
The current market capitalization is $4.3 million, with an average trading volume of 2,134,395. The biotechnology industry has shown recent volatility
</li>
</ol>

CRDO

Credo Tech rose 3.26% in pre-market; Generation Essentials Group/The fell 3.26% in pre-market; Aptevo Therapeutics rose 89.36% in pre-market; 89bio rose 82.80% in pre-market; AquaBounty Technologies rose 54.39% in pre-market

Pre-market hot trades in US stocks: Credo Tech up 3.26% in pre-market; Generation Essentials Group/The down 3.26% in pre-market